Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
Oncology
Prevalence
24.0 / 100K
Incidence
10.6 / 100K/yr
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)?
There are 1 clinical trial targeting Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC) tracked by BioSniper.
What is the prevalence of Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)?
The estimated prevalence of Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC) is approximately 24.0 per 100,000 population.
Deep-dive into Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis